Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst

This article was originally published in The Tan Sheet

Executive Summary

Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.

You may also be interested in...



Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets

Infirst changes the Mylanta Maximum Strength lemon-mint liquid with a "smoother, creamier formulation" and adds a vanilla caramel-flavored version and another liquid product, Mylanta Tonight, featuring a honey chamomile flavor. Also new are Mylanta Gas Minis chewable anti-gas tablets.

Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets

Infirst changes the Mylanta Maximum Strength lemon-mint liquid with a "smoother, creamier formulation" and adds a vanilla caramel-flavored version and another liquid product, Mylanta Tonight, featuring a honey chamomile flavor. Also new are Mylanta Gas Minis chewable anti-gas tablets.

Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan

The London firm announces Unicough cough/cold product’s launch after reviewing clinical trial results, but holds off on a Flarin ibuprofen launch until completing a trial. “We’re very, very pleased with this, although originally we wanted to be there slightly earlier,” says CEO Manfred Scheske.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS107543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel